Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer

This publication has 43 references indexed in Scilit:

• Novel Estrogen Receptor-Targeted Agents for Breast Cancer
  Current Treatment Options in Oncology, 2023
• Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2)
  Breast Cancer, 2023
• Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
  The Lancet Oncology, 2022
• 212MO AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC)
  Annals of Oncology, 2022
• Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women
  European Journal of Drug Metabolism and Pharmacokinetics, 2020
• Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer
  Molecular and Cellular Endocrinology, 2019
• Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer
  JAMA Oncology, 2016
• Modulation of nuclear receptor activity by the F domain
  Molecular and Cellular Endocrinology, 2015
• Structure–function relationship of estrogen receptor α and β: Impact on human health
  Molecular Aspects of Medicine, 2006
• The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
  Cell, 1988